Table 2.
Initial clinical manifestations in PR3/MPO-ANCA-positive patients with idiopathic vasculitides and antithyroid DIDs
| Patients with idiopathic vasculitides (n = 56) | Patients with antithyroid DIDs (n = 16) | |
| Systemic | 56 (100) | 16 (100) |
| Arthralgia/myalgia | 56(100) | 16 (100) |
| Fever >38.5°C | 48 (86) | 4 (25)*** |
| Weight loss >2 kg a month | 47 (84) | 5 (31)*** |
| Renal | 42 (75) | 3 (19)*** |
| Acute renal failure | 25 (45) | 1(6)** |
| Proteinuria, hematuria | 17 (30) | 2 (12) |
| Lung | 28 (50) | 3 (19)* |
| Infiltrate | 15 (27) | 2 (12) |
| Nodules | 10 (18) | 1 (6) |
| hemoptysis | 14 (25) | 1 (6) |
| Pulmonary-renal syndrome | 22 (39) | 1 (6)* |
| Skin | 14 (25) | 10 (62.5)** |
| Necrosis | 11(20) | 2 (12) |
| Gangrene | 3 (5) | 0 |
| Purpura | 5 (9) | 1 (6) |
| Urticaria-like vasculitis | 0 | 5 (31) *** |
| Urticaria | 0 | 2 (12.5)* |
| Gastrointestinal tract | 7 (12) | 0 |
| Ear, nose | 15 (27) | 0* |
| Eyes | 7 (12) | 0 |
| Nervous system | 26 (46) | 1 (6)** |
| Central | 13 (20) | 0 |
| Peripheral | 15 (27) | 1 (6) |
All values represent numbers of patients (%). *p < 0.05 **p < 0.01 ***p < 0.001. ANCA, antineutrophil cytoplasmic antibodies; DID, drug-induced autoimmune disease; MPO, myeloperoxidase; PR3, proteinase 3.